Charting a pathway to follow-on biologics

被引：0
|
作者：
Greb, Erik
机构：
来源：
Pharmaceutical Technology | 2009年 / 33卷 / 06期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：36 / 42
相关论文
共 50 条
  • [41] Follow-on biologics: data exclusivity and the balance between innovation and competition
    Grabowski, Henry
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) : 479 - 488
  • [42] Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics
    Zhang, Nan
    Yang, Jun
    Chow, Shein-Chung
    Endrenyi, Laszlo
    Chi, Eric
    STATISTICS IN MEDICINE, 2013, 32 (03) : 424 - 433
  • [43] Biosimilar epoetins and other "follow-on'' biologics: Update on the European experiences
    Jelkmann, Wolfgang
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) : 771 - 780
  • [44] Complex Drugs and Biologics: Scientific and Regulatory Challenges for Follow-on Products
    J. Michael Nicholas
    Drug information journal : DIJ / Drug Information Association, 2012, 46 : 197 - 206
  • [45] Complex Drugs and Biologics: Scientific and Regulatory Challenges for Follow-on Products
    Nicholas, J. Michael
    DRUG INFORMATION JOURNAL, 2012, 46 (02): : 197 - 206
  • [46] Experience of reviewing the follow-on biologics including Somatropin and erythropoietin in Japan
    Arato, Teruyo
    Yamaguchi, Teruhide
    BIOLOGICALS, 2011, 39 (05) : 289 - 292
  • [47] The FDA and follow-on biologics - Navigating the issues surrounding biologics & likely outcome of FDA generic deliberation
    Romza-Kutz, DJ
    GENETIC ENGINEERING NEWS, 2006, 26 (06): : 8 - 9
  • [48] Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
    Sarpatwari, Ameet
    Choudhry, Niteesh K.
    Avorn, Jerry
    Kesselheim, Aaron S.
    PLOS MEDICINE, 2015, 12 (03)
  • [49] Coping with the regulatory realities of follow-on biologics and the nuances of US and European regulations
    Falk J.I.
    Davidson R.A.
    Drug information journal : DIJ / Drug Information Association, 2010, 44 (2): : 137 - 145
  • [50] Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability
    Davis, Gregory C.
    Beals, John M.
    Johnson, Craig
    Mayer, Mark H.
    Meiklejohn, Bruce I.
    Mitlak, Bruce H.
    Roth, Jody L.
    Towns, John K.
    Veenhuizen, Melissa
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1655 - 1661
12345